Improved outcomes using unmanipulated haploidentical hematopoietic stem cells combined with third‐party umbilical cord blood transplantation for non‐malignant diseases in children: The experience of a single center

2021 ◽  
Author(s):  
Xiangfeng Tang ◽  
Zhang Yu ◽  
Liu Ping ◽  
Wei Lu ◽  
Yuanfang Jing ◽  
...  
Keyword(s):  
Stem Cells ◽  
Umbilical Cord Blood ◽  
Cord Blood Transplantation ◽  
Third Party ◽  
Malignant Diseases ◽  
Umbilical Cord Blood Transplantation ◽  
Single Center ◽  
Hematopoietic Stem ◽  
Blood Transplantation ◽  
Improved Outcomes

Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis

Blood ◽  
2010 ◽  
Vol 116 (4) ◽  
pp. 649-652 ◽  
Author(s):  
Shinsuke Takagi ◽  
Yasunori Ota ◽  
Naoyuki Uchida ◽  
Koichi Takahashi ◽  
Kazuya Ishiwata ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Cord Blood Transplantation ◽  
Donor Cell ◽  
Umbilical Cord Blood Transplantation ◽  
Hematopoietic Stem ◽  
Blood Transplantation ◽  
Marrow Fibrosis ◽  
Reduced Intensity

Abstract Although allogeneic hematopoietic stem cell transplantation has recently been applied to patients with myelofibrosis with reproducible engraftment and resolution of marrow fibrosis, no data describe the outcomes of umbilical cord blood transplantation. We describe 14 patients with primary (n = 1) and secondary myelofibrosis (n = 13) who underwent reduced-intensity umbilical cord blood transplantation. Conditioning regimens included fludarabine and graft-versus-host disease prophylaxis composed cyclosporine/tacrolimus alone (n = 6) or a combination of tacrolimus and mycophenolate mofetil (n = 8). Thirteen patients achieved neutrophil engraftment at a median of 23 days. The cumulative incidence of neutrophil and platelet engraftment was 92.9% at day 60 and 42.9% at day 100, respectively. Posttransplantation chimerism analysis showed full donor type in all patients at a median of 14 days. The use of umbilical cord blood could be feasible even for patients with severe marrow fibrosis, from the viewpoint of donor cell engraftment.

Sign in / Sign up

Export Citation Format

Share Document